S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
NOTICE: Your retirement is in immediate danger (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Biden and GOP rush to finalize debt ceiling deal, shore up support to prevent default
NOTICE: Your retirement is in immediate danger (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
'Succession' fans brace for series finale of Emmy-winning hit drama
NOTICE: Your retirement is in immediate danger (Ad)
Turkey's Erdogan wins 5th term as president, extending rule into 3rd decade
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
NOTICE: Your retirement is in immediate danger (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Biden and GOP rush to finalize debt ceiling deal, shore up support to prevent default
NOTICE: Your retirement is in immediate danger (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
'Succession' fans brace for series finale of Emmy-winning hit drama
NOTICE: Your retirement is in immediate danger (Ad)
Turkey's Erdogan wins 5th term as president, extending rule into 3rd decade
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
NOTICE: Your retirement is in immediate danger (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Biden and GOP rush to finalize debt ceiling deal, shore up support to prevent default
NOTICE: Your retirement is in immediate danger (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
'Succession' fans brace for series finale of Emmy-winning hit drama
NOTICE: Your retirement is in immediate danger (Ad)
Turkey's Erdogan wins 5th term as president, extending rule into 3rd decade
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
NOTICE: Your retirement is in immediate danger (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Biden and GOP rush to finalize debt ceiling deal, shore up support to prevent default
NOTICE: Your retirement is in immediate danger (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
'Succession' fans brace for series finale of Emmy-winning hit drama
NOTICE: Your retirement is in immediate danger (Ad)
Turkey's Erdogan wins 5th term as president, extending rule into 3rd decade
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed

Viridian Therapeutics (VRDN) Stock Forecast, Price & News

$23.73
-0.08 (-0.34%)
(As of 05/26/2023 ET)
Compare
Today's Range
$23.34
$24.02
50-Day Range
$22.57
$29.67
52-Week Range
$9.84
$39.00
Volume
272,021 shs
Average Volume
720,342 shs
Market Capitalization
$1.02 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$45.08

Viridian Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
90.0% Upside
$45.08 Price Target
Short Interest
Bearish
10.11% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.80mentions of Viridian Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$871,257 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.25) to ($4.57) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

395th out of 1,012 stocks

Medical Laboratories Industry

9th out of 24 stocks


VRDN stock logo

About Viridian Therapeutics (NASDAQ:VRDN) Stock

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Receive VRDN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viridian Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VRDN Stock News Headlines

Viridian Therapeutics Has Promise
3 Free Stock Picks per Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Bear market expert makes new prediction
Nobody believed Larry Benedict's prediction in February 2020. The DOW plunged 3.5%, and he told CNBC, "It seems like there's much more to come." Within a month, the market plummeted 34%. Then, nobody believed Larry at the start of last year, either. He predicted that "all the indexes will be negative for the year," with the Nasdaq leading the way. Once again, he was spot-on.
Analyst Ratings for Viridian Therapeutics
Viridian Therapeutics (VRDN) Gets a Buy from Credit Suisse
Wedbush Keeps Their Buy Rating on Viridian Therapeutics (VRDN)
See More Headlines
Receive VRDN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viridian Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VRDN Company Calendar

Last Earnings
5/09/2023
Today
5/28/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VRDN
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$45.08
High Stock Price Forecast
$51.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+90.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
11 Analysts

Profitability

Net Income
$-129,870,000.00
Net Margins
-10,419.10%
Pretax Margin
-10,419.10%

Debt

Sales & Book Value

Annual Sales
$1.77 million
Book Value
$5.00 per share

Miscellaneous

Free Float
41,200,000
Market Cap
$1.02 billion
Optionable
Not Optionable
Beta
0.95

Key Executives

  • Scott D. Myers
    President, Chief Executive Officer & Director
  • Kristian Franz Humer
    Chief Financial, Accounting & Business Officer
  • Vahe Bedian
    Chief Scientist
  • Barrett Katz
    Chief Medical Officer
  • Lara Meisner
    Secretary, Senior Vice President & General Counsel













VRDN Stock - Frequently Asked Questions

Should I buy or sell Viridian Therapeutics stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viridian Therapeutics in the last year. There are currently 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VRDN shares.
View VRDN analyst ratings
or view top-rated stocks.

What is Viridian Therapeutics' stock price forecast for 2023?

11 Wall Street analysts have issued 12-month price targets for Viridian Therapeutics' shares. Their VRDN share price forecasts range from $40.00 to $51.00. On average, they predict the company's share price to reach $45.08 in the next year. This suggests a possible upside of 90.0% from the stock's current price.
View analysts price targets for VRDN
or view top-rated stocks among Wall Street analysts.

How have VRDN shares performed in 2023?

Viridian Therapeutics' stock was trading at $29.21 at the beginning of the year. Since then, VRDN stock has decreased by 18.8% and is now trading at $23.73.
View the best growth stocks for 2023 here
.

Are investors shorting Viridian Therapeutics?

Viridian Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 4,360,000 shares, an increase of 24.9% from the April 30th total of 3,490,000 shares. Based on an average daily volume of 604,000 shares, the days-to-cover ratio is currently 7.2 days.
View Viridian Therapeutics' Short Interest
.

When is Viridian Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our VRDN earnings forecast
.

How were Viridian Therapeutics' earnings last quarter?

Viridian Therapeutics, Inc. (NASDAQ:VRDN) issued its earnings results on Tuesday, May, 9th. The company reported ($1.61) EPS for the quarter, missing analysts' consensus estimates of ($1.00) by $0.61. The business earned $0.10 million during the quarter, compared to analyst estimates of $0.10 million. Viridian Therapeutics had a negative net margin of 10,419.10% and a negative trailing twelve-month return on equity of 89.08%. The company's revenue for the quarter was down 54.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.98) earnings per share.

What is Viridian Therapeutics' stock symbol?

Viridian Therapeutics trades on the NASDAQ under the ticker symbol "VRDN."

Who are Viridian Therapeutics' major shareholders?

Viridian Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.43%), State Street Corp (5.57%), Commodore Capital LP (5.08%), Perceptive Advisors LLC (4.03%), Pictet Asset Management SA (2.42%) and Logos Global Management LP (2.20%). Insiders that own company stock include Barrett Katz, Fairmount Funds Management Llc, Jonathan Violin, Lara Meisner, Life Sciences Public F Frazier and Scott Dunseth Myers.
View institutional ownership trends
.

How do I buy shares of Viridian Therapeutics?

Shares of VRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Viridian Therapeutics' stock price today?

One share of VRDN stock can currently be purchased for approximately $23.73.

How much money does Viridian Therapeutics make?

Viridian Therapeutics (NASDAQ:VRDN) has a market capitalization of $1.02 billion and generates $1.77 million in revenue each year. The company earns $-129,870,000.00 in net income (profit) each year or ($4.66) on an earnings per share basis.

How can I contact Viridian Therapeutics?

Viridian Therapeutics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The official website for the company is www.viridiantherapeutics.com. The company can be reached via phone at (617) 272-4600, via email at daniel@lifesciadvisors.com, or via fax at 760-537-4101.

This page (NASDAQ:VRDN) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -